When to Get Body Contouring Surgery After Semaglutide Weight Loss — and Why Weight Regain Is a Concern

Systematic review and meta-analysis of MEDLINE, Embase, Web of Science, and PubMed. From 555 identified studies, 12 RCTs and prospective observational studies met inclusion criteria, encompassing 13,947 patients. The researchers calculated time to weight loss plateau (defined as ≥1 month with <3% weight loss) and weight recurrence rates after drug discontinuation.

As millions of people lose significant weight on semaglutide (Ozempic/Wegovy), demand for body contouring surgery to remove excess skin has surged — a phenomenon dubbed the 'Ozempidemic' in plastic surgery. This review provides the first evidence-based timing guidance, but also sounds a warning: unlike bariatric surgery weight loss (which is largely permanent), semaglutide weight loss reverses substantially after stopping the drug. Surgeons and patients need to plan accordingly.

The explosion of GLP-1 drug use for weight loss has created an entirely new patient population seeking plastic surgery — people who've lost substantial weight without surgery but now have excess skin. Unlike bariatric surgery patients (who have decades of surgical outcome data), GLP-1 weight loss patients represent uncharted territory for plastic surgeons. This review is among the first to provide evidence-based guidance, but the weight regain data introduces a fundamental question the field hasn't faced before: should body contouring be performed while patients stay on the drug indefinitely?

Only 2 of the 12 included studies assessed weight recurrence after drug discontinuation, limiting confidence in the weight regain estimates. The review focused on semaglutide specifically — results may differ for tirzepatide or other GLP-1 drugs. Long-term outcomes of body contouring surgery performed during or after GLP-1 therapy have not yet been studied directly.